uniQure NV QURE 深 沪
等待开盘 10-01 09:30:00 美东时间
24.44
-0.070
-0.29%
华盛通- 最 高26.68
- 今 开24.92
- 成交量 457.10万股
- 最 低 24.15
- 昨 收 24.51
- 总市值 16.95亿
- 52周最高 71.50
- 市盈率 静 --
- 换手率 6.59%
- 52周最低 8.73
- 委 比 64.23%
- 总股本 6936.64万
- 历史最高 82.49
- 量 比 0.82
- 振 幅 10.32%
- 历史最低 3.73
- 每 手 1
- 风险率 14.35%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Goldman Sachs Maintains Neutral on uniQure, Lowers Price Target to $31
Goldman Sachs analyst Salveen Richter maintains uniQure (NASDAQ:QURE) with a Neutral and lowers the price target from $46 to $31.
09-30 23:49
Hewlett Packard Enterprise, Capital Bancorp, FormFactor And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Nasdaq Composite gaining over 100 points on Wednesday. Shares of Hewlett Packard Enterprise Co (NYSE:HPE) rose during Wednesday’s session after the company announced it raised its FY27 networking segment revenue growth guidance. Also, the company announced an order ...
09-30 21:55
Why Is uniQure Stock Sinking on Tuesday?
uniQure N.V. (NASDAQ:QURE) stock is trading lower on Tuesday after the company shared mixed long-term data from ongoing Phase 1/2 clinical studies evaluating ifezuntirgene inilparvovec for Huntington’s disease. 36-Month Clinical Results And BLA Pathway In the 36-month analysis, high-dose patients de...
09-29 22:28
William Blair Reinstates Outperform on uniQure
William Blair analyst Sami Corwin reinstates uniQure (NASDAQ:QURE) with a Outperform.
09-03 03:36
uniQure Submits Biologics License Application to FDA for Accelerated Approval of Ifezuntirgene Inilparvovec (AMT-130), Gene Therapy for Huntington’s Disease
uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the submission of a Biologics License Application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for the accelerated approval of...
09-02 19:10
uniQure Charts Accelerated Path With AMT‑130
uniQure N.V. (($QURE)) has held its Q2 earnings call. Read on for the main high...
08-17 08:30
美股大行评级 | 绩后重锤！Meta惨遭16家大行下调目标价；高通、Arm、泛林集团、波士顿科学也遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持TOMI Environmental Solutions"买入"评级，目标价从3.5美元升至7美元；Canaccord Genuity：维持Viking Therapeutics"买入"评级，目标价从107美元升至114美元
07-31 11:43
Barclays Maintains Overweight on uniQure, Lowers Price Target to $60
Barclays analyst Eliana Merle maintains uniQure (NASDAQ:QURE) with a Overweight and lowers the price target from $65 to $60.
07-30 19:55
财报速睇 | uniQure NV 2026财年Q2营收0.06亿美元，同比增长11.0%；归母净利润亏损0.81亿美元，同比亏损扩大114.9%
华盛资讯7月29日讯，uniQure NV公布2026财年Q2业绩，公司Q2营收0.06亿美元，同比增长11.0%，归母净利润亏损0.81亿美元，同比亏损扩大114.9%。
07-29 19:35
财报速睇 | uniQure NV 2026财年Q2营收0.06亿美元，同比增长11.0%；归母净利润亏损0.81亿美元，同比亏损扩大114.9%
华盛资讯7月29日讯，uniQure NV公布2026财年Q2业绩，公司Q2营收0.06亿美元，同比增长11.0%，归母净利润亏损0.81亿美元，同比亏损扩大114.9%。
07-29 19:19
